These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21878655)

  • 1. Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
    Ewton DZ; Hu J; Vilenchik M; Deng X; Luk KC; Polonskaia A; Hoffman AF; Zipf K; Boylan JF; Friedman EA
    Mol Cancer Ther; 2011 Nov; 10(11):2104-14. PubMed ID: 21878655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
    Hu J; Deng H; Friedman EA
    Int J Cancer; 2013 May; 132(10):2258-69. PubMed ID: 23114871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.
    Deng X; Ewton DZ; Friedman E
    Cancer Res; 2009 Apr; 69(8):3317-24. PubMed ID: 19351855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirk regulates the exit of colon cancer cells from quiescence.
    Jin K; Ewton DZ; Park S; Hu J; Friedman E
    J Biol Chem; 2009 Aug; 284(34):22916-25. PubMed ID: 19542220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/RB2.
    Hu J; Nakhla H; Friedman E
    Int J Cancer; 2011 Jul; 129(2):307-18. PubMed ID: 20857490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mirk/dyrk1B kinase is upregulated following inhibition of mTOR.
    Deng X; Hu J; Ewton DZ; Friedman E
    Carcinogenesis; 2014 Sep; 35(9):1968-76. PubMed ID: 24590896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.
    Deng X; Ewton DZ; Li S; Naqvi A; Mercer SE; Landas S; Friedman E
    Cancer Res; 2006 Apr; 66(8):4149-58. PubMed ID: 16618736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
    Jin K; Park S; Ewton DZ; Friedman E
    Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.
    Becker W
    FEBS J; 2018 Apr; 285(7):1203-1211. PubMed ID: 29193696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase.
    Deng X; Mercer SE; Shah S; Ewton DZ; Friedman E
    J Biol Chem; 2004 May; 279(21):22498-504. PubMed ID: 15010468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mirk/dyrk1B Kinase in Ovarian Cancer.
    Friedman E
    Int J Mol Sci; 2013 Mar; 14(3):5560-75. PubMed ID: 23528858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.
    Gao J; Yang X; Yin P; Hu W; Liao H; Miao Z; Pan C; Li N
    Int J Oncol; 2012 Apr; 40(4):1203-9. PubMed ID: 22159921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.
    Gao J; Zheng Z; Rawal B; Schell MJ; Bepler G; Haura EB
    Cancer Biol Ther; 2009 Sep; 8(17):1671-9. PubMed ID: 19633423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
    Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
    Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirk/Dyrk1B in cancer.
    Friedman E
    J Cell Biochem; 2007 Oct; 102(2):274-9. PubMed ID: 17583556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mirk/Dyrk1B mediates survival during the differentiation of C2C12 myoblasts.
    Mercer SE; Ewton DZ; Deng X; Lim S; Mazur TR; Friedman E
    J Biol Chem; 2005 Jul; 280(27):25788-801. PubMed ID: 15851482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirk kinase inhibition blocks the in vivo growth of pancreatic cancer cells.
    Deng X; Friedman E
    Genes Cancer; 2014 Sep; 5(9-10):337-47. PubMed ID: 25352950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirk kinase inhibition targets ovarian cancer ascites.
    Deng X; Hu J; Cunningham MJ; Friedman E
    Genes Cancer; 2014 May; 5(5-6):201-11. PubMed ID: 25061503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells.
    Hu J; Friedman E
    Genes Cancer; 2010 Aug; 1(8):803-811. PubMed ID: 21113238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
    Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
    J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.